New TP receptor antagonists

Researchers at CIRM have synthesized and evaluated new series of original 2-aryloxy/arylamino-5-cyanobenzenesulfonylureas as thromboxane A2 receptor (TP receptor) antagonists. Based on functional pharmacological test, several compounds were found to be as potent as the 2-arylamino-5-nitrobenzenesulfonylurea reference compound BM-573, supporting the view that the bio-isosteric replacement of the nitro group by a cyano group was tolerated. […]

Cardiac Markers

We study new necrosis and fibrosis cardiac biomarkers in athletes to show their specificity as well as to highlight a cardiac biomarker helpful to discover potential risk of cardiac event during exercise. Interested in these projects? Drop us an email []. We are looking forward collaborating with you!

Stability testing

Stability testing is performed after storage in defined conditions according to standard and accelerated ICH conditions. We provide you with different range of storage conditions. All storage rooms are fully-controlled with 24/7 monitoring and alert systems. Our services include: Support in designing studies for real-time Development and validation of “stability indicating methods” Examination of stability-relevant […]

Thrombotic diseases

Clinical management of cardiovascular thrombotic diseases and participation in several international studies in acute coronary syndromes. Looking for clinical advice or support, or preparing for a clinical study? We will help you set up a cost-effective and time-efficient study! Get in touch with our experts [].


At Belgian level, CHU de Liège coordinates the European multicenter registry which is in charge to evaluate current practices in terms of diagnosis and management of cardiac toxicity of breast cancer treatments (COT registry: EACVI/HFA Cardiac Oncology Toxicity Registry in Breast Cancer: EURObservational Research Program of the European Society of Cardiology). In addition, our team evaluates […]

Valvular Heart Disease

Our team has been working for 10 years on valvular heart disease and highlighted several factors of poor clinical outcome through biomarker assay  (BNP, ST2, etc), the use of advanced echocardiographic techniques (study of myocardial deformation, ultrasound effort, etc) and the assessment of functional capacity. CHU de Liège has created the ‘Heart Valve Clinic’, regrouping a multidisciplinary team […]

P2X1 transgenic mice

We have generated transgenic mice overexpressing the human P2X1 ion channel in the megakaryocytic cell lineage. Platelets from transgenic mice exhibited a gain of P2X1 ionotropic activity as determined by more prominent P2X1– mediated Ca2+ influx and platelet shape change. P2X1 overexpression enhanced platelet secretion and aggregation evoked by collagen, convulxin, a GPVI-selective agonist, or […]

Abdominal aortic aneurysms

A study carried out by the teams at CHU de Liège revealed that recourse to the PET-CT medical imaging method was efficient in detecting aneurysms that are likely to rupture. They are currently exploring if a correlation between PET-CT images and the presence of specific molecules in the samples of aortic wall taken from the areas of high metabolic […]

Abdominal aortic aneurysm

Teams at the CHU hospital and the ULg are on the trail of markers that can predict the instability of abdominal aneurysms. They examined, among other things, the proteins in the extracellular matrix of the aortic walls and shown a correlation between the instability of an aneurysm and the presence of MMP-9 and -2, enzymes that participate […]

New mechanisms of Platelet activation

In order to identify new mechanisms or candidate genes involved in platelet biology, our team generated a cohort of healthy individuals. A genome-wide association study is ongoing to identify genetic loci associated with platelet reactivity. Interested in these projects? Drop us an email []. We are looking forward collaborating with you!